|
New Phase II results show that the novel biological therapy ACZ885 (canakinumab) is significantly more effective than an injectable corticosteroid at reducing pain and preventing recurrent attacks or 'flares' in patients with hard-to-treat gout, one of the most painful forms of arthritis.
(1888PressRelease) October 20, 2009 - The study met its primary endpoint by showing that during acute gout flares, ACZ885 reduced pain faster and more effectively than the injectable corticosteroid triamcinolone acetonide[1], a potent steroid with sustained effect used to treat severe inflammatory conditions (p ### |
